our companies

The Personalized Medicine Initiative supports commercialization activities for implementation of personalized medicine. The PMI helps companies with product definition, market research, intellectual property consultation and protection, business plan development, project management and fundraising, nurturing the translation of promising technologies and services into commercial products to enhance human health and cultivate an ecosystem for personalized medicine.


PMI_Companies_ContextualGenomics_160330_Proof03

 Contextual Genomics

Contextual Genomics is a privately held company launched in 2012 to develop and deliver genomic-based molecular diagnostics to cancer patients. Contextual Genomics is developing a suite of genomics based cancer tests to improve cancer prevention, treatment and monitoring. With deep expertise, multiple genomics-based cancer tests and strategic alliances in place, they are leading this shift towards personalized cancer care.

see initiative →

PMI_Companies_Genxys_160330_Art

GenXys Healthcare Systems

The vision of GenXys is to improve care for individual patients through the use of genomic information. Products will enable physicians and pharmacists to tailor advice to individuals using the GenXys clinical decision support systems in association with clinically effective genetic markers.

see initiative →


PMI_Companies_MicrobiomeInsights_160330_Art

Microbiome Insights

Microbiome Insights is a service company providing microbiome analysis for academic and industrial researchers. Microbiome Insights has the systems and expertise needed to add cutting edge microbiome analysis to your study.

see initiative →


PMI_Companies_MolecularYou_160330_Art

Molecular You

Molecular You will use longitudinal, integrated Omics datasets to provide preventive insight and improve diagnosis and early disease detection. By establishing a baseline of a person’s molecular makeup and monitoring these data over time, trends towards health or disease can be detected, radically empowering people to take control over their own health.

see initiative →


PMI_Companies_ME_160330_Art

Personalized Biomarkers Inc.

Personalized Biomarkers Inc. is dedicated to identifying and translating personalized approaches to managing and treating diabetes more effectively and safely. Identifying biomarkers for the development of diagnostics to guide prescription has the potential to reduce adverse drug reactions and improve outcomes, while saving patients and the healthcare system in avoidable ineffective prescribing and treatment of adverse drug reactions.

see initiative →


PMI_Companies_Acuitas_160330_Art

Acuitas Therapeutics

Acuitas Therapeutics is a biotechnology company that works with partners and customers to develop new or improved medicines based on internationally recognized capabilities in nanotechnology-based pharmaceutical product development. Acuitas provides delivery solutions for molecular therapeutics using lipid nanoparticles.


PMI_Companies_Cyon_160330_Art

Cyon Therapeutics

Cyon Therapeutics uses technology developed at the University of British Columbia to enhance the body’s ability to neutralize and clear bacterial toxins that cause sepsis.


   

ME Therapeutics

“Reawakening your immune response against cancer”
ME Therapeutics develops drugs targeting immune cell dysfunction in cancer.


PMI_Companies_Mesentech_160330_Art

MesenTech Inc.

Mesentech Inc is developing novel therapeutics designed to accelerate bone healing and maintain bone health.


PMI_Companies_PrimaryPeptides_160330_Art

Primary Peptides

Primary Peptides develops innovative peptide drugs using protected platform technology focusing on severe diseases with large drug markets including cardiovascular disease, brain diseases and cancer.


PMI_Companies_PrecisionNanosystems_160330_Art

Precision NanoSystems

Precision NanoSystems powers the development of precision medicine by providing scientists with an integrated platform of products and support, helping advance innovative nanotechnology solutions for the understanding of the molecular basis of disease.


PMI_Companies_Synaptitude_160330_Art

Synaptitude

Synaptitude Brain Health Inc. aims to bring revolutionary advances in brain imaging, genomics and neurocognitive assessments to the general public for the benefit of human brain health. Synaptitude combines sophisticated research and technical analyses to provide clients with the most comprehensive brain health assessments.



advisors

The PMI gets strategic advice from an expert local Commercialization Advisory Board and from international advisors

KARA BORTONE, PHD
Head of Company Sourcing, JLABS
ALAN CHIU
Product Lead & VC
SAMI HAMADÉ
Partner, Apple Tree Partners
OSSAMA HASSANEIN
Chairman, Rising Tide Fund
BASSAM KADRY, MD
Director of Technology Discovery, Stanford MedicineX
SARAH KELLY
Principal, Kaiser Permanente Ventures
BRENT MACDONALD
Director, HP Enterprise
DION MADSEN
Senior Managing Partner, BDC Capital
FARZAD NAIMI
Founder, Managing Partner, NAIMIgroup
MATT PASIUK
Trade Commissioner, Life Sciences, Consulate General of Canada
ANIL PATEL
Google Life Sciences
MELINDA RICHTER
Head of Johnson & Johnson Innovation, JLABS
MARYANN RUSSELL
Wealth Management Market Leader, VP, Bank of the West BNP Paribas
BERN SHEN
Executive in Residence, Cleveland Clinic Innovations
BUZZ STEWART, PHD
VP and Chief R&D Officer, Sutter Health
JENNIFER VANCINI
Director of BD, Global Partnerships, Telefonica
LAMIA WAHBA, PHD
Postdoctoral Fellow, Stanford University School of Medicine
DAVID WATSON
CEO, Cal INDEX